Literature DB >> 15613107

Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L.

Masayuki Nagasawa1, Yi Zhu, Takeshi Isoda, Daisuke Tomizawa, Sukeyuki Itoh, Michiko Kajiwara, Tomohiro Morio, Shigeaki Nonoyama, Norio Shimizu, Shuki Mizutani.   

Abstract

CD40 ligand (CD40L) is expressed not only on activated T cells but also on activated platelets. A soluble CD40 ligand (sCD40L) is released from the activated T cells and platelets by ill-defined proteolytic process in vitro. It has been reported that sCD40L is elevated in the serum of patients with systemic lupus erythematosus, unstable angina, essential thrombocythemia, and autoimmune thrombocytopenic purupura. However, source of sCD40L in vivo remains to be elucidated. We investigated the serial sCD40L in the serum in patients undergoing allogeneic stem cell transplantation and compared with the platelets number and soluble IL2R, which is a marker of activated T cells. The value of sCD40L was well correlated with platelet number or thrombopoiesis. In cases of severe graft vs. host disease with markedly increased sIL2R, sCD40L was not increased in vivo. These results indicate that sCD40L in vivo is released mainly from the platelets or in the process of platelet production but not from the activated T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15613107     DOI: 10.1111/j.1600-0609.2004.00342.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

1.  Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD.

Authors:  Chi Ma; Qiong Fu; Laurence P Diggs; John C McVey; Justin McCallen; Simon Wabitsch; Benjamin Ruf; Zachary Brown; Bernd Heinrich; Qianfei Zhang; Umberto Rosato; Sophie Wang; Linda Cui; Jay A Berzofsky; David E Kleiner; Dale B Bosco; Long-Jun Wu; Chunwei Walter Lai; Yaron Rotman; Changqing Xie; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Cell       Date:  2022-09-01       Impact factor: 38.585

2.  High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer.

Authors:  Zoltan Herold; Magdolna Herold; Gyorgy Herczeg; Agnes Fodor; Attila Marcell Szasz; Magdolna Dank; Aniko Somogyi
Journal:  World J Clin Cases       Date:  2022-05-06       Impact factor: 1.534

Review 3.  Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.

Authors:  Anna M Leung; Agnes Fermin Lee; Junko Ozao-Choy; Romela Irene Ramos; Omid Hamid; Steven J O'Day; Myung Shin-Sim; Donald L Morton; Mark B Faries; Peter A Sieling; Delphine J Lee
Journal:  Front Oncol       Date:  2014-05-16       Impact factor: 6.244

4.  Inflammatory marker trajectories associated with frailty and ageing in a 20-year longitudinal study.

Authors:  Leonard Daniël Samson; Anne-Marie Buisman; José A Ferreira; H Susan J Picavet; W M Monique Verschuren; Annemieke Mh Boots; Peter Engelfriet
Journal:  Clin Transl Immunology       Date:  2022-02-09

5.  New frontiers for platelet CD154.

Authors:  Antoine Dewitte; Annabelle Tanga; Julien Villeneuve; Sébastien Lepreux; Alexandre Ouattara; Alexis Desmoulière; Christian Combe; Jean Ripoche
Journal:  Exp Hematol Oncol       Date:  2015-03-01

6.  Levels of human platelet-derived soluble CD40 ligand depend on haplotypes of CD40LG-CD40-ITGA2.

Authors:  Chaker Aloui; Antoine Prigent; Sofiane Tariket; Caroline Sut; Jocelyne Fagan; Fabrice Cognasse; Tahar Chakroun; Olivier Garraud; Sandrine Laradi
Journal:  Sci Rep       Date:  2016-04-20       Impact factor: 4.379

7.  Age of Postmenopause Women: Effect of Soy Isoflavone in Lipoprotein and Inflammation Markers.

Authors:  Gladys Roxana Rocha Barrasa; Natalia González Cañete; Luis Emilio Valladares Boasi
Journal:  J Menopausal Med       Date:  2018-12-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.